Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742 | Director · Chief Development Officer | June 11, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADIAL PHARMACEUTICALS, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,647 |
Reported balance
After 2026-06-11 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 61,647 · Balance 61,647 F1: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora. F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. |
| Common StockSEC Table I · non-derivative | Direct | 297,491 |
Reported balance
After 2026-06-12 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-06-12 · Grant · Acquired 232,417 · Balance 297,491 F4: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Matt and Alli Davidson Trust | 3,427 |
Reported balance
After 2026-06-11 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 3,427 · Balance 3,427 F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F3: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement. F6: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust. |
| Series A Preferred StockSEC Table I · non-derivative | Direct | 1,822.13 |
Reported balance
After 2026-06-11 transaction · row 4
1 source rowRow 4 · 2026-06-11 · Grant · Acquired 1,822.13 · Balance 1,822.13 F1: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora. F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F5: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock. |
| Series A Preferred StockSEC Table I · non-derivative | IndirectBy Matt and Alli Davidson Trust | 1,923.428 |
Reported balance
After 2026-06-11 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-06-11 · Grant · Acquired 101.298 · Balance 1,923.428 F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement. F3: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement. F5: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock. F6: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2036-06-12 | Direct | 232,417 |
Reported balance
After 2026-06-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-12 · Grant · Acquired 232,417 · Balance 232,417 F7: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.
F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.
F3: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.
F4: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.
F5: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.
F6: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.
F7: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verrica Pharmaceuticals Inc.
Report date September 05, 2019 · Filed September 09, 2019
Section 16 reporting ended · disclosed 2019-09-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,556,179 |
Ending reported balance
After 2019-09-09 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2019-09-05 · Sale · Disposed 3,100 · Balance 2,572,393 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2019-09-06 · Sale · Disposed 3,802 · Balance 2,568,591 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2019-09-06 · Sale · Disposed 4,712 · Balance 2,563,879 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2019-09-06 · Sale · Disposed 1,400 · Balance 2,562,479 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2019-09-09 · Sale · Disposed 6,300 · Balance 2,556,179 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F6: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2019 Filed Feb 1, 2019 22:11 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 4,598 | $11.84 | $54,440.32 |
DisclosureSEC source: 0001209191-19-006515 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,001,189 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.30 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2019 Filed Jan 29, 2019 22:38 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 4,020 | $11.34 | $45,586.80 |
DisclosureSEC source: 0001209191-19-005818 · doc4.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005,787 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.75 to $11.655, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 22:38 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,100 | $10.72 | $33,232.00 |
DisclosureSEC source: 0001209191-19-005818 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,009,807 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.42 to $11.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 22:38 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 600 | $11.12 | $6,672.00 |
DisclosureSEC source: 0001209191-19-005818 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012,907 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.09 to $11.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 22:38 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,500 | $10.54 | $26,350.00 |
DisclosureSEC source: 0001209191-19-005818 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,013,507 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.01 to $10.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 24, 2019 Filed Jan 24, 2019 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 900 | $10.31 | $9,279.00 |
DisclosureSEC source: 0001209191-19-005203 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,016,007 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.21 to $10.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2019 Filed Jan 24, 2019 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 600 | $10.23 | $6,138.00 |
DisclosureSEC source: 0001209191-19-005203 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,016,907 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.17 to $10.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,600 | $9.97 | $15,952.00 |
DisclosureSEC source: 0001209191-19-005203 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017,507 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $9.84 to $10.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2019 Filed Jan 18, 2019 21:58 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,984 | $10.32 | $30,794.88 |
DisclosureSEC source: 0001209191-19-004576 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,019,107 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.25 to $10.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:58 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,181 | $10.18 | $22,202.58 |
DisclosureSEC source: 0001209191-19-004576 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,022,091 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:58 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 600 | $10.29 | $6,174.00 |
DisclosureSEC source: 0001209191-19-004576 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,024,272 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.20 to $10.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2019 Filed Jan 15, 2019 22:28 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 600 | $10.14 | $6,084.00 |
DisclosureSEC source: 0001209191-19-003765 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,024,872 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 22:28 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 4,519 | $10.39 | $46,952.41 |
DisclosureSEC source: 0001209191-19-003765 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,025,472 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.13 to $10.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 22:28 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,900 | $10.84 | $31,436.00 |
DisclosureSEC source: 0001209191-19-003765 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,029,991 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.57 to $11.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 10, 2019 Filed Jan 10, 2019 22:33 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,200 | $11.34 | $36,288.00 |
DisclosureSEC source: 0001209191-19-003298 · doc4.xml · nonDerivative · entry 5 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,032,891 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.05 to $11.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 09, 2019 Filed Jan 10, 2019 22:33 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,300 | $11.70 | $15,210.00 |
DisclosureSEC source: 0001209191-19-003298 · doc4.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,036,091 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.365 to $11.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 09, 2019 Filed Jan 10, 2019 22:33 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,700 | $10.73 | $28,971.00 |
DisclosureSEC source: 0001209191-19-003298 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,037,391 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.35 to $11.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 22:33 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,550 | $11.26 | $17,453.00 |
DisclosureSEC source: 0001209191-19-003298 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,040,091 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.01 to $11.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 22:33 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 7,052 | $10.48 | $73,904.96 |
DisclosureSEC source: 0001209191-19-003298 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,041,641 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $9.96 to $10.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 23:26 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,700 | $11.84 | $43,808.00 |
DisclosureSEC source: 0001209191-19-002625 · doc4.xml · nonDerivative · entry 6 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,048,693 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F7 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.755 to $11.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 23:26 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 7,977 | $11.43 | $91,177.11 |
DisclosureSEC source: 0001209191-19-002625 · doc4.xml · nonDerivative · entry 5 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,052,393 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.74 to $11.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 23:26 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,700 | $10.36 | $38,332.00 |
DisclosureSEC source: 0001209191-19-002625 · doc4.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,060,370 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $9.67 to $10.6575, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 23:26 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 799 | $9.78 | $7,814.22 |
DisclosureSEC source: 0001209191-19-002625 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,064,070 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $9.61 to $9.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 23:26 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,500 | $8.82 | $22,050.00 |
DisclosureSEC source: 0001209191-19-002625 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,064,869 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.60 to $9.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 23:26 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 14,600 | $8.43 | $123,078.00 |
DisclosureSEC source: 0001209191-19-002625 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067,369 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.25 to $8.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2019 Filed Jan 2, 2019 22:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 200 | $7.89 | $1,578.00 |
DisclosureSEC source: 0001209191-19-000399 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,081,969 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.835 to $7.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 22:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 500 | $8.18 | $4,090.00 |
DisclosureSEC source: 0001209191-19-000399 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,082,169 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.02 to $8.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 300 | $8.60 | $2,580.00 |
DisclosureSEC source: 0001209191-19-000399 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,082,669 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.35 to $8.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 27, 2018 Filed Dec 27, 2018 23:01 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 700 | $8.39 | $5,873.00 |
DisclosureSEC source: 0001209191-18-064213 · doc4.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,082,969 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.13 to $8.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 26, 2018 Filed Dec 27, 2018 23:01 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,100 | $8.76 | $9,636.00 |
DisclosureSEC source: 0001209191-18-064213 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,083,669 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.40 to $9.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 26, 2018 Filed Dec 27, 2018 23:01 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,700 | $7.82 | $13,294.00 |
DisclosureSEC source: 0001209191-18-064213 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,084,769 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.24 to $8.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 24, 2018 Filed Dec 27, 2018 23:01 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 600 | $6.78 | $4,068.00 |
DisclosureSEC source: 0001209191-18-064213 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,086,469 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $6.63 to $6.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 22:14 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 6,500 | $7.07 | $45,955.00 |
DisclosureSEC source: 0001209191-18-063961 · doc4.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,087,069 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $6.64 to $7.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:14 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,022 | $7.80 | $7,971.60 |
DisclosureSEC source: 0001209191-18-063961 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,093,569 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.46 to $8.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:14 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,300 | $7.11 | $23,463.00 |
DisclosureSEC source: 0001209191-18-063961 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,094,591 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $6.50 to $7.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 22:14 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,617 | $8.71 | $14,084.07 |
DisclosureSEC source: 0001209191-18-063961 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,097,891 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.32 to $8.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2018 Filed Dec 18, 2018 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 2,210 | $9.19 | $20,309.90 |
DisclosureSEC source: 0001209191-18-063260 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,099,508 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.80 to $9.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 1,305 | $9.94 | $12,971.70 |
DisclosureSEC source: 0001209191-18-063260 · doc4.xml · nonDerivative · entry 2 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,101,718 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $9.60 to $10.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 700 | $10.07 | $7,049.00 |
DisclosureSEC source: 0001209191-18-063260 · doc4.xml · nonDerivative · entry 1 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,103,023 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 29, 2018 Filed Mar 29, 2019 21:50 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 4,815 | $10.88 | $52,387.20 |
DisclosureSEC source: 0001209191-19-021828 · doc4.xml · nonDerivative · entry 3 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,799,001 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.60 to $11.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2018 Filed Feb 20, 2019 22:16 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 100 | $11.76 | $1,175.50 |
DisclosureSEC source: 0001209191-19-011659 · doc4.xml · nonDerivative · entry 4 Davidson Matt · CIK 0001741937 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,944,838 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.